8,750 Shares in Agios Pharmaceuticals, Inc. $AGIO Acquired by E Fund Management Co. Ltd.

Key Points

• E Fund Management Co. Ltd. has acquired a new stake in Agios Pharmaceuticals valued at approximately $256,000, purchasing 8,750 shares in the first quarter.
• Several institutional investors, including Jefferies Financial Group and Deutsche Bank AG, have significantly changed their positions in Agios, either by acquiring new shares or increasing current holdings.
• Despite a negative earnings report of ($1.93) EPS, Agios Pharmaceuticals reported a revenue of $12.50 million, exceeding analyst expectations.

E Fund Management Co. Ltd. purchased a new position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 8,750 shares of the biopharmaceutical company's stock, valued at approximately $256,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. GAMMA Investing LLC lifted its position in Agios Pharmaceuticals by 9,296.6% during the first quarter. GAMMA Investing LLC now owns 8,175 shares of the biopharmaceutical company's stock valued at $240,000 after buying an additional 8,088 shares during the period. Envestnet Asset Management Inc. lifted its position in Agios Pharmaceuticals by 3.3% during the fourth quarter. Envestnet Asset Management Inc. now owns 24,805 shares of the biopharmaceutical company's stock valued at $815,000 after buying an additional 795 shares during the period. Northern Trust Corp lifted its position in Agios Pharmaceuticals by 0.9% during the fourth quarter. Northern Trust Corp now owns 595,480 shares of the biopharmaceutical company's stock valued at $19,567,000 after buying an additional 5,372 shares during the period. Federated Hermes Inc. lifted its position in Agios Pharmaceuticals by 4.4% during the fourth quarter. Federated Hermes Inc. now owns 13,691 shares of the biopharmaceutical company's stock valued at $450,000 after buying an additional 582 shares during the period. Finally, Patient Square Capital LP purchased a new position in Agios Pharmaceuticals during the fourth quarter valued at $4,000,000.

Insider Activity

In other news, CFO Cecilia Jones sold 1,780 shares of Agios Pharmaceuticals stock in a transaction dated Tuesday, June 24th. The stock was sold at an average price of $33.54, for a total transaction of $59,701.20. Following the transaction, the chief financial officer directly owned 30,049 shares of the company's stock, valued at $1,007,843.46. The trade was a 5.59% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Brian Goff sold 18,700 shares of Agios Pharmaceuticals stock in a transaction dated Tuesday, June 24th. The shares were sold at an average price of $33.54, for a total value of $627,198.00. Following the transaction, the chief executive officer directly owned 105,401 shares in the company, valued at approximately $3,535,149.54. The trade was a 15.07% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 57,448 shares of company stock worth $2,026,141. 4.30% of the stock is currently owned by corporate insiders.

Agios Pharmaceuticals Stock Performance

Shares of AGIO traded up $0.60 during trading hours on Wednesday, hitting $36.82. The company had a trading volume of 400,667 shares, compared to its average volume of 991,101. The firm has a fifty day moving average price of $36.66 and a 200-day moving average price of $32.83. The stock has a market capitalization of $2.14 billion, a price-to-earnings ratio of 3.35 and a beta of 0.80. Agios Pharmaceuticals, Inc. has a 52-week low of $23.42 and a 52-week high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported ($1.93) EPS for the quarter, missing the consensus estimate of ($1.74) by ($0.19). The business had revenue of $12.50 million during the quarter, compared to the consensus estimate of $9.46 million. Agios Pharmaceuticals had a negative return on equity of 3.49% and a net margin of 1,590.42%. Research analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have commented on AGIO shares. Bank of America lowered their price objective on Agios Pharmaceuticals from $52.00 to $51.00 and set a "buy" rating for the company in a research report on Tuesday, July 22nd. Wall Street Zen lowered Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Monday, May 19th. Finally, Scotiabank lowered their price target on Agios Pharmaceuticals from $71.00 to $65.00 and set a "sector outperform" rating for the company in a research report on Monday, July 28th. Six analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $56.33.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.